

# **ASX ANNOUNCEMENT**

## Wednesday 23rd October 2019

#### Information Booklet - Retail Entitlement Offer

Palla Pharma Limited (ASX: PAL) (**PAL**) has today despatched the Information Booklet in respect of the Retail Entitlement Offer and the accompanying personalised Entitlement and Acceptance Forms to eligible retail shareholders.

The Retail Offer Booklet was released to ASX on Monday 21 October. The Retail Offer Booklet will also be available on the ASX website www.asx.com.au.

The Retail Offer Booklet contains information in relation to PAL's fully underwritten pro rata 2 for 5 accelerated non-renounceable entitlement offer.

The Retail Entitlement Offer will close at 5.00pm (Melbourne time) on Monday 11 November.

Only Eligible Retail Shareholders may participate in the Retail Entitlement Offer. The eligibility criteria for the Retail Entitlement Offer is set out in the Retail Offer Booklet.

For further information on the Entitlement Offer you should call the PAL Offer Information Line on call 1300 794 935 from 8.30am to 5.30pm (Melbourne time) Monday to Friday during the Retail Offer Period. If you have any further questions, you should contact your stockbroker, accountant or other professional adviser.

### For more information please contact:

# **Jarrod Ritchie**

Chief Executive Officer Palla Pharma Limited +61 3 9301 0800

### **Brendan Middleton**

Chief Financial Officer Palla Pharma Limited +61 3 9301 0800

### **Adrian Mulcahy**

Investor Relations Market Eye +61 438 630 422 ir@pallapharma.com

### **About Palla Pharma Limited:**

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.